Trevi Therapeutics amends bylaws to update proxy rules and meeting procedures

Trevi Therapeutics, Inc.

Eliminated requirement for stockholder list to be available at meeting.
Added provisions for adjourning meetings due to technical failure in remote communication.
Enhanced disclosure requirements for stockholder nominations under universal proxy rules (Rule 14a-19).
Company may disregard nominations if stockholders fail to comply with Rule 14a-19 solicitation requirements.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.98

Trevi Therapeutics, Inc.: On April 13, 2023, the Board approved an amendment and restatement of the bylaws to eliminate the requirement to make the stockholder list available during meetings, address adjournment due to technical failures in remote meetings, and revise procedural mechanics and disclosure requirements in light (effective 2023-04-13).

Change: bylaw amendment
Effective: 2023-04-13

Exact text from the filing

On April 13, 2023, the Board of Directors of Trevi Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-012870

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.